You are here

Nucala

GSK looks to stand out in the severe asthma space with at-home injections for kids 6 to 11 years old

GSK looks to stand out in the severe asthma space with at-home injections for kids 6 to 11 years old

Endpoints

Flag link:

GlaxoSmithKline's Nucala beats AZ's Fasenra to the IL-5 punch in nasal polyps

GlaxoSmithKline's Nucala beats AZ's Fasenra to the IL-5 punch in nasal polyps

Fierce Pharma

Flag link:

GlaxoSmithKline's Nucala targets rival AstraZeneca with FDA nod for rare white blood cell disease

GlaxoSmithKline's Nucala targets rival AstraZeneca with FDA nod for rare white blood cell disease

Fierce Pharma

hypereosinophilic syndrome

Flag link:

GSK's national TV push for Nucala gives another meaning to 'new normal'

GSK's national TV push for Nucala gives another meaning to 'new normal'

Fierce Pharma

Flag link:

GSK's asthma drug Nucala gets speedy review for rare blood disorder

GSK's asthma drug Nucala gets speedy review for rare blood disorder

Endpoints

hypereosinophilic syndrome

priority review

Flag link:

GSK's asthma biologic Nucala is one step closer to approval in key chronic rhinosinusitis population

GSK's asthma biologic Nucala is one step closer to approval in key chronic rhinosinusitis population

Endpoints

clinical trials

Flag link:

Nucala works in rare inflammatory disease, says GSK

Nucala works in rare inflammatory disease, says GSK

PM Live

clinical trials

hypereosinophilic syndromes

Flag link:

GlaxoSmithKline's Nucala cuts severe asthma attacks in 'reassuring' interim real-world data

GlaxoSmithKline's Nucala cuts severe asthma attacks in 'reassuring' interim real-world data

Fierce Pharma

real world data

Flag link:

Glaxo's Asthma Drug Nucala Gets FDA Nod for Pediatric Use

Glaxo's Asthma Drug Nucala Gets FDA Nod for Pediatric Use

Yahoo/Zacks.com

eosinophilic asthma

Flag link:

GlaxoSmithKline's Nucala scores convenience boost with at-home dosing options

GlaxoSmithKline's Nucala scores convenience boost with at-home dosing options

Fierce Pharma

eosinophilic asthma

Flag link:

GSK seeks pediatric indication for Nucala in severe eosinophilic asthma

GSK seeks pediatric indication for Nucala in severe eosinophilic asthma

Pharmaceutical Business Review

eosinophilic asthma

Flag link:

GSK touts Nucala data after COPD miss

GSK touts Nucala data after COPD miss

Biopharma Dive

Flag link:

The pain won’t stop. GSK ends the week with a slapdown on its Nucala application for COPD

The pain won’t stop. GSK ends the week with a slapdown on its Nucala application for COPD

Endpoints

complete response letter

Flag link:

EC approves GSK's Nucala for kids with severe asthma

EC approves GSK's Nucala for kids with severe asthma

Biopharma Dive

Flag link:

FDA staff raises efficacy doubts on GSK's lung disease treatment

FDA staff raises efficacy doubts on GSK's lung disease treatment

Yahoo/Reuters

Flag link:

NICE says yes to AstraZeneca’s Fasenra, but only when its GSK rival can’t be used

NICE says yes to AstraZeneca’s Fasenra, but only when its GSK rival can’t be used

Fierce Pharma

Flag link:

Glaxo aims to lure patients from Novartis' Xolair with Nucala switching study

Glaxo aims to lure patients from Novartis' Xolair with Nucala switching study

Fierce Pharma

Flag link:

GlaxoSmithKline, now vying with AstraZeneca, scores brand-new market for Nucala

GlaxoSmithKline, now vying with AstraZeneca, scores brand-new market for Nucala

Fierce Pharma

eosinophilic granulomatosis with polyangiitis

Flag link:

GlaxoSmithKline's Nucala, buoyed by its medical organization, ready to 'fiercely compete' with AstraZeneca

GlaxoSmithKline's Nucala, buoyed by its medical organization, ready to 'fiercely compete' with AstraZeneca

Fierce Pharma

eosinophilic asthma

Flag link:

Struggling in R&D, GSK lines up an FDA pitch on COPD with mixed data

Struggling in R&D, GSK lines up an FDA pitch on COPD with mixed data

Endpoints

Flag link:

Pages